ASX:PYCBiotechs
Why PYC Therapeutics (ASX:PYC) Is Up 10.5% After Narrowing Its Full-Year Net Loss
PYC Therapeutics Limited recently reported full-year results for the period ended June 30, 2026, with revenue rising to A$39.68 million from A$26.17 million and its net loss narrowing to A$43.34 million compared with A$50.3 million a year earlier.
The improvement in both top-line revenue and loss per share suggests the business is scaling its operations while gradually reducing the financial burden on shareholders.
We will now examine how this combination of higher revenue and a smaller...